Europe Generic Drugs Market 2025-2035

Description

List of Tables

Europe Generic Drugs Market Size, Share & Trends Analysis Report, By Application (Cancer, CVD, Musculoskeletal Diseases, Infectious Diseases, Neurology, Diabetes, and Others), By Route of Administration (Oral, Topical, Injectable, and Inhaler), Forecast Period (2025-2035)

Industry Overview

Europe generic drugs market was valued at $123.4 billion in 2024 and is projected to reach $201.9 billion by 2035, growing at a CAGR of 4.7% during the forecast period (2025-2035). The Europe generic drugs market has been witnessing steady growth driven by increasing demand for cost-effective treatments and the rising prevalence of chronic diseases. Companies such as Teva Pharmaceutical Industries Ltd and Sandoz Group AG are expanding their portfolios to include high-demand cardiovascular and oncology generics, meeting the evolving healthcare needs. Enhanced regulatory support and streamlined approval processes have further accelerated market expansion. Additionally, the adoption of oral and injectable formulations has improved patient compliance and accessibility. Strategic collaborations and acquisitions among leading players are also contributing to market consolidation.

Market Dynamics

Expansion of Oncology Generic Drugs

The European generic drugs market is witnessing a notable increase in oncology-focused products, driven by rising cancer prevalence and demand for affordable therapies. Viatris Inc. has recently introduced several generic oncology medications, enabling wider patient access across multiple countries. Improved formulation techniques and cost-effective manufacturing processes are supporting this growth. Health systems are increasingly favoring generics to manage treatment costs, encouraging further investment. This trend highlights the strategic focus of key manufacturers on high-need therapeutic areas.

Growth in Cardiovascular and Diabetes Generics

Cardiovascular and diabetes medications continue to dominate the European generics segment due to high patient populations and long-term treatment requirements. Hikma Pharmaceuticals PLC has expanded its portfolio to include widely prescribed oral cardiovascular and anti-diabetic generics. Enhanced patient adherence through oral formulations and increased reimbursement support are boosting uptake. Additionally, partnerships with regional distributors are accelerating product reach. The rising focus on chronic disease management is positioning these therapeutic areas as key growth drivers. Manufacturers are actively targeting these segments to capitalize on sustained demand.

Market Segmentation

Based on the route of administration, the market is segmented into oral, topical, injectable, and inhaler.
Based on the application, the market is segmented into cancer, CVD, musculoskeletal diseases, infectious diseases, neurology, diabetes, and others.

Cardiovascular Disease (CVD) Segment to Lead the Market with the Largest Share

The European generic drugs market is experiencing substantial growth driven by the increasing prevalence of cardiovascular diseases. Teva Pharmaceutical Industries Ltd has expanded its cardiovascular product offerings, providing cost-effective alternatives for commonly prescribed therapies. Rising awareness about heart health and preventive treatment strategies is fueling demand for generics. Healthcare systems across Europe are encouraging the adoption of affordable cardiovascular medications to manage growing patient loads. Improved distribution networks are also enhancing access to these treatments.

Oral : A Key Segment in Market Growth

The market for generic drugs in Europe is benefiting from the widespread adoption of oral formulations. Sandoz Group AG has introduced a range of oral generics, improving patient convenience and treatment adherence. Oral medications are preferred due to ease of administration, especially for chronic conditions requiring long-term therapy. Cost-effective production and regulatory incentives have further accelerated market expansion. Increased patient awareness and demand for self-administered therapies are also supporting this trend.

Regional Outlook

Europe generic drugs market is further divided by countries, including Germany, the UK, France, Spain, Italy, Russia, and the Rest of Europe.

Rising Demand for Affordable Therapies across Multiple Therapeutic Areas in Germany

Germany's generic drugs market is expanding steadily, owing to rising demand for affordable therapies across multiple therapeutic areas. Hikma Pharmaceuticals PLC has strengthened its presence by offering a diverse portfolio of generic medications, catering to cardiovascular and metabolic disorders. Supportive government policies and reimbursement programs are enabling wider patient access. Strategic collaborations with local distributors are enhancing market reach and efficiency. Technological improvements in drug formulation and production are also contributing to market competitiveness.

Market Players Outlook

The major companies operating in the Europe generic drugs market include Hikma Pharmaceuticals PLC, Sandoz Group AG, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Viatris Inc., among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.

Recent Developments

In December 2024, Sawai Pharmaceutical Co., Ltd. announced the listing of five generic drugs with 10 strengths in the NHI (National Health Insurance) drug price list. Sawai's product line now includes 332 compounds with 786 strengths. These additions further reinforce Sawai's position as a leading generic pharmaceutical manufacturer in Japan, with a continually expanding portfolio and presence in the NHI listing.
In April 2024, the European Commission approved Pfizer's EMBLAVEO for Patients with Multidrug-Resistant Infections and Limited Treatment Options. EMBLAVEO is the first B-lactam/B-lactamase inhibitor antibiotic combination approved in the European Union for treating serious infections in adult patients caused by multidrug-resistant Gram-negative bacteria, including metallo-B-lactamase-producing bacteria.

The Report Covers:

Market value data analysis of 2024 and forecast to 2035.
Annualized market revenues ($ million) for each market segment.
Country-wise analysis of major geographical regions.
Key companies operating in the Europe generic drugs market. Based on the availability of data, information related to new products and relevant news is also available in the report.
Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
Analysis of market-entry and market expansion strategies.
Competitive strategies by identifying 'who-stands-where' in the market.

Product Code: OMR2023561

1. Report Summary

Current Industry Analysis and Growth Potential Outlook
Europe Generic Drugs Market Sales Analysis - Route of Administration | Application | ($ Million)
Europe Generic Drugs Market Sales Performance of Top Countries
1.1. Research Methodology
Primary Research Approach
Secondary Research Approach
1.2. Market Snapshot

2. Market Overview and Insights

2.1. Scope of the Study
2.2. Analyst Insight & Current Market Trends
- 2.2.1. Key Europe Generic Drugs Industry Trends
- 2.2.2. Market Recommendations

3. Market Determinants

3.1. Market Drivers
- 3.1.1. Drivers For Europe Generic Drugs Market: Impact Analysis
3.2. Market Pain Points and Challenges
- 3.2.1. Restraints For Europe Generic Drugs Market: Impact Analysis
3.3. Market Opportunities

4. Competitive Landscape

4.1. Competitive Dashboard - Europe Generic Drugs Market Revenue and Share by Manufacturers
Generic Drugs Product Comparison Analysis
Top Market Player Ranking Matrix
4.2. Key Company Analysis
- 4.2.1. Hikma Pharmaceuticals PLC
  - 4.2.1.1. Overview
  - 4.2.1.2. Product Portfolio
  - 4.2.1.3. Financial Analysis (Subject to Data Availability)
  - 4.2.1.4. SWOT Analysis
  - 4.2.1.5. Business Strategy
- 4.2.2. Sandoz Group AG
  - 4.2.2.1. Overview
  - 4.2.2.2. Product Portfolio
  - 4.2.2.3. Financial Analysis (Subject to Data Availability)
  - 4.2.2.4. SWOT Analysis
  - 4.2.2.5. Business Strategy
- 4.2.3. Sun Pharmaceutical Industries Ltd.
  - 4.2.3.1. Overview
  - 4.2.3.2. Product Portfolio
  - 4.2.3.3. Financial Analysis (Subject to Data Availability)
  - 4.2.3.4. SWOT Analysis
  - 4.2.3.5. Business Strategy
- 4.2.4. Teva Pharmaceutical Industries Ltd.
  - 4.2.4.1. Overview
  - 4.2.4.2. Product Portfolio
  - 4.2.4.3. Financial Analysis (Subject to Data Availability)
  - 4.2.4.4. SWOT Analysis
  - 4.2.4.5. Business Strategy
- 4.2.5. Viatris Inc.
  - 4.2.5.1. Overview
  - 4.2.5.2. Product Portfolio
  - 4.2.5.3. Financial Analysis (Subject to Data Availability)
  - 4.2.5.4. SWOT Analysis
  - 4.2.5.5. Business Strategy
4.3. Top Winning Strategies by Market Players
- 4.3.1. Merger and Acquisition
- 4.3.2. Product Launch
- 4.3.3. Partnership And Collaboration

5. Europe Generic Drugs Market Sales Analysis by Route of Administration ($ Million)

5.1. Oral
5.2. Topical
5.3. Injectable
5.4. Inhaler

6. Europe Generic Drugs Market Sales Analysis by Application ($ Million)

6.1. Cancer
6.2. CVD
6.3. Musculoskeletal Diseases
6.4. Infectious Diseases
6.5. Neurology
6.6. Diabetes
6.7. Others

7. Regional Analysis

7.1. Europe Generic Drugs Market Sales Analysis - Route of Administration | Application | Country ($ Million)
Macroeconomic Factors for Europe
- 7.1.1. Germany
- 7.1.2. UK
- 7.1.3. France
- 7.1.4. Spain
- 7.1.5. Italy
- 7.1.6. Russia
- 7.1.7. Rest of Europe

8. Company Profiles

8.1. Amgen Inc.
- 8.1.1. Quick Facts
- 8.1.2. Company Overview
- 8.1.3. Product Portfolio
- 8.1.4. Business Strategies
8.2. AstraZeneca PLC
- 8.2.1. Quick Facts
- 8.2.2. Company Overview
- 8.2.3. Product Portfolio
- 8.2.4. Business Strategies
8.3. Aurobindo Pharma Ltd.
- 8.3.1. Quick Facts
- 8.3.2. Company Overview
- 8.3.3. Product Portfolio
- 8.3.4. Business Strategies
8.4. Baxter International Inc.
- 8.4.1. Quick Facts
- 8.4.2. Company Overview
- 8.4.3. Product Portfolio
- 8.4.4. Business Strategies
8.5. Boehringer Ingelheim
- 8.5.1. Quick Facts
- 8.5.2. Company Overview
- 8.5.3. Product Portfolio
- 8.5.4. Business Strategies
8.6. Fresenius SE & Co. KGaA
- 8.6.1. Quick Facts
- 8.6.2. Company Overview
- 8.6.3. Product Portfolio
- 8.6.4. Business Strategies
8.7. Glenmark Pharmaceuticals Ltd.
- 8.7.1. Quick Facts
- 8.7.2. Company Overview
- 8.7.3. Product Portfolio
- 8.7.4. Business Strategies
8.8. Hikma Pharmaceuticals PLC
- 8.8.1. Quick Facts
- 8.8.2. Company Overview
- 8.8.3. Product Portfolio
- 8.8.4. Business Strategies
8.9. KRKA d.d.
- 8.9.1. Quick Facts
- 8.9.2. Company Overview
- 8.9.3. Product Portfolio
- 8.9.4. Business Strategies
8.10. Mylan N.V.
- 8.10.1. Quick Facts
- 8.10.2. Company Overview
- 8.10.3. Product Portfolio
- 8.10.4. Business Strategies
8.11. Novartis AG
- 8.11.1. Quick Facts
- 8.11.2. Company Overview
- 8.11.3. Product Portfolio
- 8.11.4. Business Strategies
8.12. Sandoz Group AG
- 8.12.1. Quick Facts
- 8.12.2. Company Overview
- 8.12.3. Product Portfolio
- 8.12.4. Business Strategies
8.13. Sanofi S.A.
- 8.13.1. Quick Facts
- 8.13.2. Company Overview
- 8.13.3. Product Portfolio
- 8.13.4. Business Strategies
8.14. Sawai Pharmaceutical Co., Ltd.
- 8.14.1. Quick Facts
- 8.14.2. Company Overview
- 8.14.3. Product Portfolio
- 8.14.4. Business Strategies
8.15. Strides Pharma Science Ltd.
- 8.15.1. Quick Facts
- 8.15.2. Company Overview
- 8.15.3. Product Portfolio
- 8.15.4. Business Strategies
8.16. Stada Arzneimittel AG
- 8.16.1. Quick Facts
- 8.16.2. Company Overview
- 8.16.3. Product Portfolio
- 8.16.4. Business Strategies
8.17. Sun Pharmaceutical Industries Ltd.
- 8.17.1. Quick Facts
- 8.17.2. Company Overview
- 8.17.3. Product Portfolio
- 8.17.4. Business Strategies
8.18. Teva Pharmaceutical Industries Ltd.
- 8.18.1. Quick Facts
- 8.18.2. Company Overview
- 8.18.3. Product Portfolio
- 8.18.4. Business Strategies
8.19. Towa Pharmaceutical Co., Ltd.
- 8.19.1. Quick Facts
- 8.19.2. Company Overview
- 8.19.3. Product Portfolio
- 8.19.4. Business Strategies
8.20. Viatris Inc.
- 8.20.1. Quick Facts
- 8.20.2. Company Overview
- 8.20.3. Product Portfolio
- 8.20.4. Business Strategies